Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Parkin DM: International variation. Oncogene23,6329–6340 (2004).
  Medline CASGoogle Scholar
• 2  Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin. Oncol.26,2–8 (1999).
  Medline CASGoogle Scholar
• 3  Rouvelas I, Zeng W, Lindblad , Viklund P, Ye W, Lagergren J: Survival after surgery for esophageal cancer: a population-based study. Lancet Oncol.6,864–870 (2005).
  MedlineGoogle Scholar
• 4  Urschel JD, Vasan HB: A meta-analysis of randomized controlled trials that compared neo-adjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg.185,538–543 (2003).
  MedlineGoogle Scholar
• 5  Fiorica F, Di Bona D, Schepis F: Preoperative chemoradiotherapy for oesophageal cancer: a systemic review and meta-analysis. Gut53,925–930 (2004).•• Meta-analysis neoadjuvant.
  Medline CASGoogle Scholar
• 6  Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs17,259–269 (1999).
  Medline CASGoogle Scholar
• 7  Baselga J, Pfister D, Cooper MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol.18,904–914 (2000).
  Medline CASGoogle Scholar
• 8  Aklilu M, Ilson DH: Targeted agents and esophageal cancer – the next step? Semin. Radiat. Oncol.17,62–69 (2007).
  MedlineGoogle Scholar
• 9  Ross JS, McKenna BJ: The HER-2/Neu oncogene in tumors of the gastrointestinal tract. Cancer Invest.19,554–568 (2001).
  Medline CASGoogle Scholar
• 10  Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23,1011–1027 (2005).•• Basic paper on vascular endothelial growth factor (VEGF) pathway.
  Medline CASGoogle Scholar
• 11  Kleespies A, Guba M, Jauch KW, Bruns CJ: Vascular endothelial growth factor in esophageal cancer. J. Surg. Oncol.87,95–104 (2004).• VEGF in esophageal cancer.
  Medline CASGoogle Scholar
• 12  Presta LG, Chen H, O’Connor SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57,4593–4599 (1997).
  Medline CASGoogle Scholar
• 13  Gorski DH, Beckett MA, Jaskowiak NT et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res.59,3374–3378 (1999).
  Medline CASGoogle Scholar
• 14  Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAID’s and esophageal cancer: a systematic review and metaanalysis. Gastroenterology124,47–56 (2003).• Meta-analysis protection of esophageal cancer.
  Medline CASGoogle Scholar
• 15  Pillsbury HC 3rd, Webster WP, Rosenman J: Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch. Otolaryngol. Head Neck Surg.112,552–553 (1986).
  MedlineGoogle Scholar
• 16  Enzinger P, Mamon H, Choi NC: Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. ASCO Gastrointestinal Cancers35,59 (2004).
  Google Scholar
• 17  Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin. Cancer Res.4,2885–2890 (1998).
  Medline CASGoogle Scholar
• 18  Minnich DJ, MacKay SLD, Camp ER, Contardo AM, Moldawer LL, Hochwald SN: Enhancement of chemotherapy response in esophageal carcinoma by inhibition of NF-κB. Proc. Am. Assoc. Cancer Res.44,1500 (2003).
  Google Scholar
• 19  Bramhall SR, Hallissey MT, Whiting J et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer86,1864–1870 (2002).•• Randomized trial on matrix metalloproteinase inhibitors.
  Medline CASGoogle Scholar
• 20  Koishi K, Yoshikawa R, Tsujimura T et al.: Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J. Gastroenterol.12,7585–7590 (2006).
  Medline CASGoogle Scholar